Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

British Journal of Cancer

Volumn 107, Issue 10, 2012, Pages 1692-1701

  Lin, Y ^a,b   Richards, F M ^a,b   Krippendorff, B F ^a,b   Bramhall, J L ^a,b   Harrington, J A ^a,b   Bapiro, T E ^a,b   Robertson, A ^c   Zheleva, D ^c   Jodrell, D I ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c CYCLACEL LTD   (United Kingdom)

Author keywords

Combination treatment; CYC3; Mitotic inhibitor; Paclitaxel; Pancreatic cancer

Indexed keywords

AURORA A KINASE; AURORA KINASE INHIBITOR; CYC 3; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SPECIFICITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CELL LINE, TUMOR; DRUG SYNERGISM; GRANULOCYTE-MACROPHAGE PROGENITOR CELLS; HUMANS; PACLITAXEL; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; STEM CELLS;

EID: 84869094120     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.450     Document Type: Article

References (46)

1. Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3(1): 51-62. (Pubitemid 37443890)
2. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(23): 3099-3108.
3. Cheung CH, Coumar MS, Hsieh HP, Chang JY (2009) Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 18(4): 379-398.
4. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3): 621-681.
5. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
6. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H (2010) Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 67(4): 945-954.
7. Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI (2011) Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 17(4): 849-860.
8. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006a) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2(9): 458-466. (Pubitemid 44266307)
9. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006b) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2(9): 458-466. (Pubitemid 44266307)
10. Gascoigne KE, Taylor SS (2008) Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14(2): 111-122.
11. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara Jr PN, Gandara DR (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14(6): 1639-1648. (Pubitemid 351471713)
12. Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, Marumoto T, Saya H, Horii A (2005a) RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 65(7): 2899-2905. (Pubitemid 40490094)
13. Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, Marumoto T, Saya H, Horii A (2005b) RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 65(7): 2899-2905. (Pubitemid 40490094)
14. Jonker DM, Visser SA, van der Graaf PH, Voskuyl RA, Danhof M (2005) Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther 106(1): 1-18. (Pubitemid 40386718)
15. Kitzen JJ, de Jonge MJ, Verweij J (2010) Aurora kinase inhibitors. Crit Rev Oncol Hematol 73(2): 99-110.
16. Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, Krumbholz RD, Schmid SM, Teicher BA (2009) Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemother Pharmacol 64(5): 1029-1038.
17. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S (2003) Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9(3): 991-997. (Pubitemid 36323702)
18. Li J, Wientjes MG, Au JL (2010) Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 12(2): 223-232.
19. Li Y, Tang K, Zhang H, Zhang Y, Zhou W, Chen X (2011) Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp. Mol Med Report 4(4): 739-746.
20. Lok W, Klein RQ, Saif MW (2010) Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs 21(4): 339-350.
21. Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Rosello S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J (2010) Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 9(10): 2844-2852.
22. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB (2011a) Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17(24): 7614-7624.
23. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB (2011b) Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17(24): 7614-7624.
24. Minton SE, LoRusso P, Lockhart AC, Saif MW, Krishnamurthi SS, Pickett-Gies CA, Wang Y, Guan S, Roben E, Stein MN (2010) A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors. J Clin Oncol 28(Suppl): Abstr e13026.
25. Negro GD, Bonato M, Gribaldo L (2001) In vitro bone marrow granulocytemacrophage progenitor cultures in the assessment of hematotoxic potential of the new drugs. Cell Biol Toxicol 17(2): 95-105. (Pubitemid 32681046)
26. Parent-Massin D (2001) Relevance of clonogenic assays in hematotoxicology. Cell Biol Toxicol 17(2): 87-94. (Pubitemid 32681045)
27. Prichard MN, Prichard LE, Baguley WA, Nassiri MR, Shipman Jr C (1991) Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. Antimicrob Agents Chemother 35(6): 1060-1065.
28. Prichard MN, Shipman Jr C (1990) A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14(4-5): 181-205. (Pubitemid 20377558)
29. Riffell JL, Zimmerman C, Khong A, McHardy LM, Roberge M (2009) Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. Cell Cycle 8(18): 3025-3038.
30. Rojanala S, Han H, Munoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ (2004) The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther 3(4): 451-457. (Pubitemid 39193722)
31. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20(4 Suppl 3): 1-15. (Pubitemid 23239390)
32. Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS (2008) Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 6: 79.
33. Sessa F, Mapelli M, Ciferri C, Tarricone C, Areces LB, Schneider TR, Stukenberg PT, Musacchio A (2005) Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol Cell 18(3): 379-391. (Pubitemid 41350542)
34. Sharma S, Kurzrock R, Gouw L, Hong DS, Jones K, Zhou X, Shi H, Fingert H, Falchook GS (2011) Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies. J Clin Oncol 29(Suppl): Abstr 3094.
35. Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y (2010a) MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 9(1): 157-166.
36. Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y (2010b) MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 9(1): 157-166.
37. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82(13): 1107-1112. (Pubitemid 20213250)
38. Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987a) Expression of a fulllength cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84(9): 3004-3008. (Pubitemid 17064766)
39. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I (1987b) The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 262(2): 505-508. (Pubitemid 17005205)
40. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3): 1112-1116.
41. Wang S, Midgley CA, Scaerou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G, McClue SJ, McInnes C, Meades C, Mezna M, Plater A, Stuart I, Thomas MP, Wood G, Clarke RG, Blake DG, Zheleva DI, Lane DP, Jackson RC, Glover DM, Fischer PM (2010a) Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-Amine aurora kinase inhibitors. J Med Chem 53(11): 4367-4378.
42. Wang X, Sinn AL, Pollok K, Sandusky G, Zhang S, Chen L, Liang J, Crean CD, Suvannasankha A, Abonour R, Sidor C, BrayMR, Farag SS (2010b) Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol 150(3): 313-325.
43. Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H (2006) Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol Cancer Ther 5(10): 2450-2458. (Pubitemid 44650908)
44. Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326(7): 455-465.
45. Wysong DR, Chakravarty A, Hoar K, Ecsedy JA (2009) The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 8(6): 876-888.
46. Zhang W, Dutschman GE, Li X, Cheng YC (2011) Quantitation of paclitaxel and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879(22): 2018-2022